Delving into the Latest Updates on JiaRay Therapeutics, Inc. with Synapse

Overview

Tags

Neoplasms

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Chemical drugs	1

一、剂量递增（第1部分）主要目的：评价JR8603 的安全性和耐受性；确定最大耐受剂量(MTD)和/II 期推荐剂量（ RP2D ）。次要目的：确定JR8603 在晚期实体瘤中的有效性；评估JR8603 的药代动力学（PK）特征。探索性目的：通过血清和肿瘤组织中生物标志物的表达以及血清Legumain 水平评估ORR。二、剂量扩展（第2部分）主要目的：确定MTD/RP2D 下JR8603 的安全性和耐受性；评估各队列有效性的初步证据。次要目的：进一步评估JR8603 的PK 特征；确定JR8603 在各队列的有效性。探索性目的：通过血清和肿瘤组织中生物标志物的表达以及血清Legumain 水平评估ORR。

[Translation]

I. Dose escalation (Part 1) Primary objectives: Evaluate the safety and tolerability of JR8603; determine the maximum tolerated dose (MTD) and/phase II recommended dose (RP2D). Secondary objectives: Determine the efficacy of JR8603 in advanced solid tumors; evaluate the pharmacokinetic (PK) characteristics of JR8603. Exploratory objectives: Evaluate ORR by the expression of biomarkers in serum and tumor tissues and serum Legumain levels. II. Dose expansion (Part 2) Primary objectives: Determine the safety and tolerability of JR8603 under MTD/RP2D; evaluate the preliminary evidence of efficacy in each cohort. Secondary objectives: Further evaluate the PK characteristics of JR8603; determine the efficacy of JR8603 in each cohort. Exploratory objectives: Evaluate ORR by the expression of biomarkers in serum and tumor tissues and serum Legumain levels.

Start Date23 Dec 2024

Sponsor / Collaborator

Jiangsu Jiarui Biotechnology Co., Ltd.

[+2]

100 Clinical Results associated with JiaRay Therapeutics, Inc.

Login to view more data

0 Patents (Medical) associated with JiaRay Therapeutics, Inc.

Login to view more data

100 Deals associated with JiaRay Therapeutics, Inc.

Login to view more data

100 Translational Medicine associated with JiaRay Therapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data